Legal & General Group
PCVX icon

Legal & General Group’s Vaxcyte PCVX Stock Holding History

Legal & General Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.66M Buy
97,451
+114
+0.1% +$6.19K ﹤0.01% 1522
2026
Q1 		$5.66M Sell
97,337
-22,964
-19% -$1.25M ﹤0.01% 1438
2025
Q4 		$5.55M Sell
120,301
-10,100
-8% -$452K ﹤0.01% 1505
2025
Q3 		$4.7M Sell
130,401
-3,161
-2% -$105K ﹤0.01% 1617
2025
Q2 		$4.34M Buy
133,562
+3,690
+3% +$121K ﹤0.01% 1617
2025
Q1 		$4.9M Buy
129,872
+6,208
+5% +$496K ﹤0.01% 1540
2024
Q4 		$10.1M Buy
123,664
+24,136
+24% +$2.4M ﹤0.01% 1159
2024
Q3 		$11.4M Buy
99,528
+3,218
+3% +$290K ﹤0.01% 1114
2024
Q2 		$7.27M Buy
96,310
+1,527
+2% +$104K ﹤0.01% 1316
2024
Q1 		$6.47M Buy
94,783
+14,780
+18% +$1.02M ﹤0.01% 1385
2023
Q4 		$5.02M Buy
80,003
+4,573
+6% +$238K ﹤0.01% 1500
2023
Q3 		$3.85M Buy
75,430
+4,851
+7% +$239K ﹤0.01% 1579
2023
Q2 		$3.52M Buy
70,579
+4,457
+7% +$211K ﹤0.01% 1646
2023
Q1 		$2.48M Buy
66,122
+39,805
+151% +$1.69M ﹤0.01% 1783
2022
Q4 		$1.26M Buy
26,317
+10,573
+67% +$415K ﹤0.01% 2074
2022
Q3 		$378K Buy
15,744
+309
+2% +$7.83K ﹤0.01% 2415
2022
Q2 		$337K Buy
15,435
+6,591
+75% +$153K ﹤0.01% 2453
2022
Q1 		$214K Buy
8,844
+727
+9% +$15.9K ﹤0.01% 2643
2021
Q4 		$194K Sell
8,117
-139
-2% -$3.23K ﹤0.01% 2736
2021
Q3 		$210K Buy
8,256
+4,124
+100% +$100K ﹤0.01% 2675
2021
Q2 		$93K Buy
4,132
+489
+13% +$10K ﹤0.01% 2765
2021
Q1 		$72K Buy
3,643
+946
+35% +$23.8K ﹤0.01% 2709
2020
Q4 		$71K Buy
2,697
+626
+30% +$23.3K ﹤0.01% 2688
2020
Q3 		$102K Buy
+2,071
New +$82.5K ﹤0.01% 2485

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Legal & General Group's PCVX Position: Q2 2026 in Review

Legal & General Group increased its Vaxcyte (PCVX) stake by 0.12% in Q2 2026, buying an estimated $6.19K and bringing the position to 97,451 shares worth $5.66M. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

Legal & General Group first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $11.4M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Legal & General Group held 97,451 shares of Vaxcyte worth $5.66M as of Q2 2026.
  • Legal & General Group bought 114 Vaxcyte shares in Q2 2026, an estimated $6.19K.
  • Vaxcyte made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1522 holding.
  • Legal & General Group first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Legal & General Group's Vaxcyte position peaked at $11.4M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.